重组人表皮生长因子对糖尿病足部溃疡疗效的临床观察

The Clinical Observation of rhEGF in the Treatment of Diabetic Foot Ulcers

目的观察重组人表皮生长因子对糖尿病足部溃疡治疗的临床效果。方法 146例确诊为Wagner分级I-III级的糖尿病足溃疡患者,随机分为对照组73例,创面外喷生理盐水,重组人表皮生长因子治疗组73例,创面外喷重组人表皮生长因子2000IU/ml,每日一次。两组敷料包扎,每日换药,比较两组创面愈合情况,肉芽组织成熟程度及有无副作用。结果重组人表皮生长因子治疗组治愈率31.5%,总体有效率93.1%显著高于对照组治愈率12.3%,总体有效率53.4%(均有P【0.01);重组人表皮生长因子治疗组溃疡肉芽组织生长情况显著好于生理盐水治疗对照组(χ2=24.63,P=0.001);重组人表皮生长因子治疗组糖尿病足的平均愈合时间(23±2.52)天显著低于对照组平均愈合时间(56±3.78)天,两组比较具有统计学差异(P【0.01);重组人表皮生长因子治疗过程中未发现有任何严重不良反应。结论重组人表皮生长因子治疗糖尿病足部溃疡具有明显的有益作用,且安全性好无副作用。

Objective To observe the clinical effects of recombinant human epidermal growth factor(rhEGF) in the treatment of diabetic foot ulcers.Methods One hundred and forty six patients with diabetic foot ulcer among Wagner grade I to III were divided into two groups randomly.73 patients were treated by physiological saline namely control group.Other 73 patients were treated by rhEGF 2000IU/ml per day namely treatment group.Conclusion With good safety and no side effect,rhEGF has an obvious therapeutic effect on diabetic foot ulcers.